Literature DB >> 31135801

The structural basis for Ras activation of PI3Kα lipid kinase.

Mingzhen Zhang1, Hyunbum Jang, Ruth Nussinov.   

Abstract

PI3Kα is a principal Ras effector that phosphorylates PIP2 to PIP3 in the PI3K/Akt/mTOR pathway. How Ras activates PI3K has been unclear: is Ras' role confined to PI3K recruitment to the membrane or does Ras activation also involve allostery? Recently, we determined the mechanism of PI3Kα activation at the atomic level. We showed the vital role and significance of conformational change in PI3Kα activation. Here, by a 'best-match for hydrogen-bonding pair' (BMHP) computational protocol and molecular dynamics (MD) simulations, we model the atomic structure of KRas4B in complex with the Ras binding domain (RBD) of PI3Kα, striving to understand the mechanism of PI3Kα activation by Ras. Point mutations T208D, K210E, and K227E disrupt the KRas4B-RBD interface in the models, in line with the experiments. We identify allosteric signaling pathways connecting Ras to RBD in the p110α subunit. However, the observed weak allosteric signals coupled with the detailed mechanism of PI3Kα activation make us conclude that the dominant mechanistic role of Ras is likely to be recruitment and restriction of the PI3Kα population at the membrane. Thus, RTK recruits the PI3Kα to the membrane and activates it by relieving its autoinhibition exerted by the nSH2 domain, leading to exposure of the kinase domain, which permits PIP2 binding. Ras recruitment can shift the PI3Kα ensemble toward a population where the kinase domain surface and the active site position and orientation favor PIP2 insertion. This work helps elucidate Ras-mediated PI3K activation and explores the structural basis for Ras-PI3Kα drug discovery.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31135801      PMCID: PMC6556208          DOI: 10.1039/c9cp00101h

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  65 in total

1.  Scalable molecular dynamics with NAMD.

Authors:  James C Phillips; Rosemary Braun; Wei Wang; James Gumbart; Emad Tajkhorshid; Elizabeth Villa; Christophe Chipot; Robert D Skeel; Laxmikant Kalé; Klaus Schulten
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

Review 2.  Phosphoinositide 3-kinases as drug targets in cancer.

Authors:  Len Stephens; Roger Williams; Phillip Hawkins
Journal:  Curr Opin Pharmacol       Date:  2005-08       Impact factor: 5.547

3.  Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Authors:  Surbhi Gupta; Antoine R Ramjaun; Paula Haiko; Yihua Wang; Patricia H Warne; Barbara Nicke; Emma Nye; Gordon Stamp; Kari Alitalo; Julian Downward
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

4.  Protein interaction data set highlighted with human Ras-MAPK/PI3K signaling pathways.

Authors:  Jian Wang; Yanzhi Yuan; Ying Zhou; Longhua Guo; Lingqiang Zhang; Xuezhang Kuai; Binwei Deng; Zhi Pan; Dong Li; Fuchu He
Journal:  J Proteome Res       Date:  2008-07-15       Impact factor: 4.466

5.  Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation.

Authors:  Heng-Yu Fan; Masayuki Shimada; Zhilin Liu; Nicola Cahill; Noritaka Noma; Yun Wu; Jan Gossen; JoAnne S Richards
Journal:  Development       Date:  2008-06       Impact factor: 6.868

6.  Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.

Authors:  Li Zhao; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-11       Impact factor: 11.205

7.  Structural insights into phosphoinositide 3-kinase catalysis and signalling.

Authors:  E H Walker; O Perisic; C Ried; L Stephens; R L Williams
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

8.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma.

Authors:  M E Pacold; S Suire; O Perisic; S Lara-Gonzalez; C T Davis; E H Walker; P T Hawkins; L Stephens; J F Eccleston; R L Williams
Journal:  Cell       Date:  2000-12-08       Impact factor: 41.582

9.  Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.

Authors:  Nabil Miled; Ying Yan; Wai-Ching Hon; Olga Perisic; Marketa Zvelebil; Yuval Inbar; Dina Schneidman-Duhovny; Haim J Wolfson; Jonathan M Backer; Roger L Williams
Journal:  Science       Date:  2007-07-13       Impact factor: 47.728

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

View more
  20 in total

Review 1.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

2.  Deciphering the selective binding mechanisms of anaplastic lymphoma kinase-derived neuroblastoma tumor neoepitopes to human leukocyte antigen.

Authors:  Wenchao Tian; Xianxian Liu; Lulu Wang; Bufeng Zheng; Kun Jiang; Guoyong Fu; Wenyu Feng
Journal:  J Mol Model       Date:  2021-04-26       Impact factor: 1.810

Review 3.  The Mystery of Rap1 Suppression of Oncogenic Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Anna A Sablina
Journal:  Trends Cancer       Date:  2020-03-02

4.  The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin.

Authors:  Hyunbum Jang; Avik Banerjee; Kendra Marcus; Lee Makowski; Carla Mattos; Vadim Gaponenko; Ruth Nussinov
Journal:  Structure       Date:  2019-09-05       Impact factor: 5.006

5.  Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases.

Authors:  Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  J Mol Biol       Date:  2020-09-10       Impact factor: 5.469

6.  Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.

Authors:  Nicholas G Martinez; David F Thieker; Leiah M Carey; Juhi A Rasquinha; Samantha K Kistler; Brian A Kuhlman; Sharon L Campbell
Journal:  J Mol Biol       Date:  2021-02-01       Impact factor: 5.469

7.  Molecular Dynamics Simulation of Lipid-Modified Signaling Proteins.

Authors:  Vinay V Nair; Alemayehu A Gorfe
Journal:  Methods Mol Biol       Date:  2021

8.  The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane.

Authors:  Hyunbum Jang; Iris Nira Smith; Charis Eng; Ruth Nussinov
Journal:  iScience       Date:  2021-04-17

9.  The mechanism of activation of monomeric B-Raf V600E.

Authors:  Ryan C Maloney; Mingzhen Zhang; Hyunbum Jang; Ruth Nussinov
Journal:  Comput Struct Biotechnol J       Date:  2021-06-04       Impact factor: 7.271

10.  The structural basis of Akt PH domain interaction with calmodulin.

Authors:  Jackson Weako; Hyunbum Jang; Ozlem Keskin; Ruth Nussinov; Attila Gursoy
Journal:  Biophys J       Date:  2021-03-26       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.